1. < Blood Cancers & Disorders
Profile picture for DMD81

MGUS Questions and Answers

Posted by DMD81 @dmdinapoli81, May 5 3:54pm

I wanted to start a discussion specifically on Monoclonal Gammopathy of Undetermined Significance (MGUS). Asking specific questions about time of diagnosis, like age, m-spike level, protein in urine level and % of bone marrow involvement. If you have any inflammatory diagnosis? Any bone or joint paint? What your Hem-onc has as your monitoring schedule? Did you do any clinical trials? Etc.

*Please stay on topic in this specific forum chat* Thank you
https://istopmm.com/risk-models-and-calculators/

Interested in more discussions like this? Go to the Blood Cancers & Disorders Support Group.

Profile picture for DMD81
DMD81 | @dmdinapoli81 | May 5 4:06pm

**Disclaimer: This information is for educational purposes. For a tailored monitoring plan, use tools like the Find a Specialist directory to consult a hematologist-oncologist.**
HERE IS THE NITTY GRITTY OF:
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a non-cancerous condition where abnormal plasma cells in the bone marrow produce a specific protein called "M-protein" (monoclonal protein). While it is generally asymptomatic, it is considered a benign precursor to blood cancers like multiple myeloma.
I WILL REPEAT: Is a non-cancerous condition, PROGRESSION RATE OF 1% A YEAR.

Core Diagnostic Criteria To be diagnosed with MGUS as of 2026, a patient must meet all of the following criteria:
M-protein levels: Less than 3.0 g/dL in the blood.
Plasma cell concentration: Less than 10% of the bone marrow.
Absence of organ damage: No "CRAB" symptoms (hypercalcemia, renal insufficiency, anemia, or bone lesions).

Risk Stratification (Mayo Clinic Model)The risk of MGUS progressing to cancer is approximately 1% per year. Doctors use three primary markers to determine an individual's specific risk: The Mayo Clinic’s 2/20/20 Criteria also to look at
M-protein level: Greater/equal to 1.5 g/dL.
Isotype: A non-IgG type (such as IgA or IgM).
FLC Ratio: An abnormal serum free light chain ratio (less than 0.26 or greater than 1.65).

Treatment and Monitoring
No Treatment: Because MGUS is typically stable and asymptomatic, it usually does not require treatment.
"Watch and Wait": Management involves regular check-ups (often yearly) with blood and urine tests to monitor M-protein levels.
Progression Risk: The risk of MGUS progressing to a more serious condition (like multiple myeloma) is low, at approximately 1% per year.

When to Consult a Specialist:
Seek further evaluation if you experience "red flag" symptoms:
Unexplained bone pain or fractures.
Persistent fatigue or shortness of breath (anemia).Numbness or tingling in hands and feet.
Foamy urine or swelling in the legs (kidney issues).

**Disclaimer: This information is for educational purposes. For a tailored monitoring plan, use tools like the Find a Specialist directory to consult a hematologist-oncologist.**
PS AI helped me with this 🙂

REPLY
1 reply
Profile picture for Ginger, Volunteer Mentor
Mentor
Ginger, Volunteer Mentor | @gingerw | May 7 12:04pm
In reply to @dmdinapoli81 "**Disclaimer: This information is for educational purposes. For a tailored monitoring plan, use tools like the..." + (show)
Profile picture for DMD81 @dmdinapoli81

**Disclaimer: This information is for educational purposes. For a tailored monitoring plan, use tools like the Find a Specialist directory to consult a hematologist-oncologist.**
HERE IS THE NITTY GRITTY OF:
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a non-cancerous condition where abnormal plasma cells in the bone marrow produce a specific protein called "M-protein" (monoclonal protein). While it is generally asymptomatic, it is considered a benign precursor to blood cancers like multiple myeloma.
I WILL REPEAT: Is a non-cancerous condition, PROGRESSION RATE OF 1% A YEAR.

Core Diagnostic Criteria To be diagnosed with MGUS as of 2026, a patient must meet all of the following criteria:
M-protein levels: Less than 3.0 g/dL in the blood.
Plasma cell concentration: Less than 10% of the bone marrow.
Absence of organ damage: No "CRAB" symptoms (hypercalcemia, renal insufficiency, anemia, or bone lesions).

Risk Stratification (Mayo Clinic Model)The risk of MGUS progressing to cancer is approximately 1% per year. Doctors use three primary markers to determine an individual's specific risk: The Mayo Clinic’s 2/20/20 Criteria also to look at
M-protein level: Greater/equal to 1.5 g/dL.
Isotype: A non-IgG type (such as IgA or IgM).
FLC Ratio: An abnormal serum free light chain ratio (less than 0.26 or greater than 1.65).

Treatment and Monitoring
No Treatment: Because MGUS is typically stable and asymptomatic, it usually does not require treatment.
"Watch and Wait": Management involves regular check-ups (often yearly) with blood and urine tests to monitor M-protein levels.
Progression Risk: The risk of MGUS progressing to a more serious condition (like multiple myeloma) is low, at approximately 1% per year.

When to Consult a Specialist:
Seek further evaluation if you experience "red flag" symptoms:
Unexplained bone pain or fractures.
Persistent fatigue or shortness of breath (anemia).Numbness or tingling in hands and feet.
Foamy urine or swelling in the legs (kidney issues).

**Disclaimer: This information is for educational purposes. For a tailored monitoring plan, use tools like the Find a Specialist directory to consult a hematologist-oncologist.**
PS AI helped me with this 🙂

Jump to this post

@dmdinapoli81 The source of this information, please?
Ginger

REPLY
Please sign in or register to post a reply.